- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
52 result(s) found for: Voice.
Displaying page 1 of 3.
EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
Sponsor Name:Antwerp University Hospital | ||
Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
Medical condition: Onco-hematological patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006497-23 | Sponsor Protocol Number: 870128 | Start Date*: 2022-07-05 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: Corticosteroid in treatment of acute laryngitis among vocal professionals | ||
Medical condition: Laryngitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003573-58 | Sponsor Protocol Number: 2025 | Start Date*: 2021-08-09 |
Sponsor Name:Antwerp University Hospital | ||
Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus) | ||
Medical condition: Onco-hematological patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004359-18 | Sponsor Protocol Number: CCTU/2012/036 | Start Date*: 2015-02-02 | |||||||||||||||||||||
Sponsor Name:University College London (UCL) hereby represented by UCL Comprehensive Clinical Trials Unit(CCTU) | |||||||||||||||||||||||
Full Title: RegenVOX: Phase I/IIa clinical trial of stem cell based tissue engineered partial laryngeal implants in adult patients with end-stage laryngotracheal stenosis with 24 months follow-up | |||||||||||||||||||||||
Medical condition: Disorder of Upper Respiratory System Laryngostenosis Tracheal Stenosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004532-43 | Sponsor Protocol Number: E-716/D9612L00095 | Start Date*: 2006-02-07 |
Sponsor Name:Klinikum Großhadern, ENT-Department | ||
Full Title: Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study | ||
Medical condition: Patients with laryngopharyngeal reflux symptoms will be treated with PPI or Placebo | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019180-10 | Sponsor Protocol Number: NCTU5248 | Start Date*: 2010-07-29 |
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Paramedic Initiated Lisinopril For Acute Stroke Treatment(PIL-FAST): A Pilot Randomised Controlled Trial | ||
Medical condition: Stroke and high blood pressure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004409-24 | Sponsor Protocol Number: AK130940 | Start Date*: 2005-06-08 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150m... | ||
Medical condition: Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005124-15 | Sponsor Protocol Number: CAMN107AIC05 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of ... | |||||||||||||
Medical condition: Adult patients with Ph+ chronic phase CML that have been treated with Imatinib for at least 2 years, are in CCyR, but have not achieved MR4.0 at study entry. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SK (Completed) SE (Completed) HU (Completed) IT (Completed) DE (Completed) NO (Completed) PT (Completed) FI (Completed) ES (Completed) IE (Completed) CZ (Completed) BG (Completed) BE (Completed) GR (Completed) DK (Completed) SI (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003803-19 | Sponsor Protocol Number: WXL101497 | Start Date*: 2004-11-10 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch... | ||
Medical condition: Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000872-13 | Sponsor Protocol Number: 202000865 | Start Date*: 2021-03-02 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Vaccination against cOvid In CancEr | ||
Medical condition: solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004227-17 | Sponsor Protocol Number: 2020-53 | Start Date*: 2022-02-24 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: INNOVATIVE TREATMENT OF SCARRED VOCAL FOLDS BY LOCAL INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION: EFFICACY VERSUS PLACEBO | ||
Medical condition: Vocal fold scars | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000614-37 | Sponsor Protocol Number: 21467 | Start Date*: 2019-05-02 |
Sponsor Name:Region Örebro Län | ||
Full Title: Kort-SGS: Does a series of intralesional steroid injections after endoscopic treatments for subglottic stenosis prolong interval between between surgical interbentions? A prospective single blinded... | ||
Medical condition: Subglottic stenosis: Idiopatic, autoimmune, traumatic. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001213-12 | Sponsor Protocol Number: HGT-FIR-096 | Start Date*: 2014-09-05 | |||||||||||
Sponsor Name:Shire Orphan Therapies, Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE... | |||||||||||||
Medical condition: ACE-I-induced angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005959-42 | Sponsor Protocol Number: CN138-502 | Start Date*: 2008-06-18 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Pat... | |||||||||||||
Medical condition: Bipolar I Mania (manic or mixed episode) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004972-74 | Sponsor Protocol Number: 20160227 | Start Date*: 2020-09-15 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta | |||||||||||||
Medical condition: Osteogenesis imperfecta (OI) is a group of genetic skeletal disorders characterized by increased bone fragility, low bone mass , and increased bone turnover contributing to osteoporosis, fracture... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GR (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003304-12 | Sponsor Protocol Number: A0081279 | Start Date*: 2013-02-12 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain | |||||||||||||
Medical condition: Chronic post-traumatic peripheral neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) BG (Completed) HU (Completed) BE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002004-24 | Sponsor Protocol Number: CV185-316 | Start Date*: 2017-02-08 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillatio... | |||||||||||||||||||||||
Medical condition: Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NO (Completed) BG (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) PL (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) SE (Completed) SK (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000184-40 | Sponsor Protocol Number: 20130173 | Start Date*: 2014-09-11 | |||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||
Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta | |||||||||||||
Medical condition: Osteogenesis Imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002505-62 | Sponsor Protocol Number: STH16404 | Start Date*: 2013-11-14 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: SarCaBon: A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain | |||||||||||||
Medical condition: Cancer-induced bone pain | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003028-35 | Sponsor Protocol Number: CTU/2016/278 | Start Date*: 2019-09-04 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trial Unit | |||||||||||||
Full Title: A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
